Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usuall...
Tremelimumab Plus Durvalumab and Platinum-Based Chemotherapy Approved for Metastatic NSCLC
Lyn Brook
FDA Updates
The FDA has approved tremelimumab (Imjudo®, AstraZeneca) in combination with durvalumab (Imfinzi®, AstraZeneca) and platinum-based chemotherapy for patients with metastatic non–small cell lung cancer (NSCLC) who have no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Tremel...
Cemiplimab-rwlc Approved for Treatment of Non–Small Cell Lung Cancer
Lyn Brook
FDA Updates
The FDA has granted approval of cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals, Inc.) in combination with platinum-based chemotherapy for treatment of advanced non–small cell lung cancer (aNSCLC) with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1) aberrations, and no prior systemic...
Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine: Blanca Ledezma, MSN, NP In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  
Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  
Selpercatinib Approved for RET Fusion-Positive Non-Small Cell Lung Cancer
Lyn Brook
FDA Updates
The FDA has granted regular approval selpercatinib (Retevmo®, Eli Lilly and Company) for treatment of adult patients with locally advanced or metastatic rearranged during transfection (RET) gene fusion non-small cell lung cancer (NSCLC). Selpercatinib previously received an accelerated approval from the FDA based on its initial trial results in May...
Pemigatinib Approved for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Lyn Brook
FDA Updates
The FDA has approved pemigatinib (Pemazyre®, Incyte Corporation) for the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with a fibroblast growth factor receptor 1 (FGFR1) rearrangement. This is the first approval and only targeted treatment for MLNs with a FGFR1 rearrangement. "Myeloid/lymphoid neoplasms with a FGFR1 rearrang...
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Trastuzumab Deruxtecan First Approval for HER2-Mutant Non–Small Cell Lung Cancer
Lyn Brook
FDA Updates
The FDA has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu®, Daiichi Sankyo Inc.) for treatment of adult patients with unresectable or metastatic non–small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) mutations. This approval is specific to individuals who have undergone previous sy...
Capmatinib Granted Regular Approval for Metastatic Non–Small Cell Lung Cancer
Lyn Brook
FDA Updates
The FDA has granted regular approval to capmatinib (Tabrecta®, Novartis Pharmaceuticals Corp.) for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) who have tumors evolving into the mesenchymal-epithelial transition exon 14 skipping (METex14) mutation. Capmatinib was previously granted accelerated approval in May 2020 ...
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Advancing Treatment for Non–Small Cell Lung Cancer: Exploring the Results of Adagrasib With Alexander Spira, MD, PhD, FACP
Lyn Brook
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Alexander Spira, MD, PhD, FACP, Director of the Thoracic and Phase I Program at the Virginia Cancer Specialists, the US Oncology Network, met with Oncology Data Advisor to discuss his presentation about adagrasib for KRAS G12–mutated non–small cell lung cancer with active central nervous system (CNS) metastases.  
Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer With Ticiana Leal, MD, and Beth Sandy, MSN, CRNP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 84% of cases are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). Th...
Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer With Mark Kris, MD, and Victoria Sherry, DNP, CRNP, AOCNP®
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer Squamous cell lung carcinoma is a distinct histologic subtype of non–small cell lung cancer (NSCLC) that accounts for approximately 25% to 30% of all NSCLC cases and is associated with approximately 30% shorter survival compared with other ...

Copyright © 2022 Oncology Data Advisor. All rights reserved.